Global Data Announces Development of Cell Therapy for Parkinson’s Disease

[의학신문·일간보사=김자연 기자] Global Data recently announced that it is planning to develop a cell therapy for Parkinson’s disease.

Based on this, cell therapy shows promising effects on non-motor symptoms of Parkinson’s disease and is expected to fill the unmet demand for existing treatments.

Notably, at this international conference on Alzheimer’s and Parkinson’s disease, Bayer’s Blue Rock attracted attention by announcing positive Phase 1 clinical trial results for NTC04802733 (bemdaneprocel), a genetically engineered cell therapy product .

It is a treatment that involves the surgical transplant of dopaminergic neural progenitor stem cells and which has proven to be effective not only on motor symptoms but also on non-motor ones, for which phase clinical trials are expected to begin this year. 2.

In other words, these cells survived 18 months after the transplant and 6 months after taking immunosuppressants, and there was only one case of serious side effects, which were due to the transplant surgery rather than the cell therapy itself. Furthermore, the dyskinesia that occurred in the existing cell transplantation test did not appear.

Furthermore, among patients who received high-dose treatment, not only were motor symptoms reduced, but neuropsychiatric symptoms, cognitive functions, and frontal lobe-related behaviors also showed improvement.

Additionally, neural progenitor stem cell treatments for Parkinson’s disease that have completed Phase 1 clinical trials and whose results have been made public include Cyto Therapeutics’ ISC-hpNSC and Celavi Biosciences’ HSCfPD.

Among these, Cyto Therapeutics’ treatment also reported improvement in non-motor symptoms in Phase I/IIa clinical trials.

Furthermore, among the stem cell treatments currently undergoing phase 1 and 2 clinical trials, Novo Nordisk’s NN-9001 and S.Biomedix’s TED-A9 are also expected to announce results, attracting attention in the future.

#Expectations #development #cell #therapy #Parkinsons #disease